TherapeuticsMD (TXMD) Non-Current Debt (2010 - 2021)

TherapeuticsMD's Non-Current Debt history runs 7 years deep, the most recent figure standing at $171.7 million for Q3 2021.

• Quarterly Non-Current Debt fell 27.55% year-over-year to $171.7 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $171.7 million (down 27.55% YoY) and the FY2020 annual result came in at $237.7 million, up 22.13% from the prior year.
• Non-Current Debt was $171.7 million for Q3 2021 at TherapeuticsMD, down from $175.3 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $243.8 million in Q2 2020 and bottomed at $73.1 million in Q2 2018.
• A 4-year average of $169.2 million and a median of $189.0 million in 2019 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2020 — Non-Current Debt jumped 231.19% — and 2021, when it decreased 28.11%.
• TherapeuticsMD's Non-Current Debt stood at $73.4 million in 2018, then surged by 165.24% to $194.6 million in 2019, then rose by 22.13% to $237.7 million in 2020, then slipped by 27.75% to $171.7 million in 2021.
• Business Quant data shows TXMD's Non-Current Debt at $171.7 million in Q3 2021, $175.3 million in Q2 2021, and $184.0 million in Q1 2021.